UCSF Research Vital to First Drug for Deadly Bone Disease
September 28, 2023
September 28, 2023
SAN FRANCISCO, California, Sept. 28 -- The University of California San Francisco campus issued the following news release:
* * *
FDA approves palovarotene to provide only treatment for people living with fibrodysplasia ossificans progressiva
* * *
The U.S. Food and Drug Administration (FDA) recently approved palovarotene (Sohonos) as the first treatment for fibrodysplasia ossifcans progressiva (FOP), a severely disabling condition that causes . . .
* * *
FDA approves palovarotene to provide only treatment for people living with fibrodysplasia ossificans progressiva
* * *
The U.S. Food and Drug Administration (FDA) recently approved palovarotene (Sohonos) as the first treatment for fibrodysplasia ossifcans progressiva (FOP), a severely disabling condition that causes . . .